What We Still Need to Know About Insulin Pumps in Type 1 Diabetes Pregnancy

Automated insulin delivery systems—commonly called 'closed-loop' pumps or artificial pancreas systems—have become more widely available and are increasingly used during Type 1 diabetes pregnancies. Despite this growth, the evidence about their real benefits and safety remains fragmented, scattered across clinical trials, smaller case studies, research reports, and qualitative interviews with patients and providers.

Existing reviews and analyses have tended to focus heavily on one outcome: how well these devices control blood sugar during pregnancy. While that's important, it tells only part of the story. Questions remain about whether these devices are truly safe, whether they actually work well in everyday practice, how they affect parents' stress and quality of life, and how healthcare systems can implement them successfully.

A new mixed-methods systematic review, currently in protocol phase, aims to pull together all available evidence on commercial automated insulin delivery systems in Type 1 diabetes pregnancy. Rather than focusing on one narrow outcome, this review will take a broader approach.

The review will look at blood sugar control metrics tailored to pregnancy (like 'time in range' measured by continuous glucose monitors), maternal health outcomes, and neonatal (newborn) outcomes. It will also examine how acceptable and feasible these devices are for pregnant people and their healthcare teams—including questions about workload for clinicians, burden on patients, and how well these systems function in different real-world settings.

This systematic review will consider the full range of available research: randomized controlled trials, observational studies, case series, qualitative interviews, and mixed-methods studies. Importantly, it will account for differences between studies—examining evidence from different insulin pump systems separately, comparing studies that started AID systems at different times in pregnancy, and considering how implementation context (the type of healthcare system or clinic) affects outcomes.

The review will also include studies of 'off-label' pregnancy use—meaning cases where pregnant people were using AID systems in ways not formally approved by device manufacturers, reflecting real-world clinical practice.

The researchers will systematically search major medical databases from 2010 onward, with an updated search before completing their analysis. Two independent reviewers will assess the quality of each study and extract data to reduce the chance of bias. Where studies are similar enough, findings will be combined into meta-analyses—a statistical method to synthesize results across multiple studies.

By bringing together scattered evidence and examining multiple outcomes—not just blood sugar—this review should give parents, clinicians, and the Type 1 diabetes community a clearer picture of what automated insulin delivery systems can and cannot do during pregnancy, and how well they work in different situations.

Source: Endocrinology, diabetes & metabolism. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.